Novel pharmacotherapies for retinal vascular diseases are pursuing the dual goal of increased efficacy and longer duration of action.
The journey is not an easy one, but meaningful progress has been made despite the hurdles, disruptions and detours found along the way. With faricimab and high-dose aflibercept already on the market and the Port Delivery System undergoing further optimization, sufficient data from trials and real-world experience have been generated to realistically support the hope that more robust disease control and less frequent administration are possible.
“These